Not enough evidentiary support: Developers and researchers should provide more evidence on how AI-enabled CDS systems may affect patient outcomes, care quality, costs of care and clinician workflow. More available evidence would help ensure the effectiveness and trustworthiness of the technology.

Patient risk assessments: Developers should provide more information about how the technology was made and trained, which would allow regulators and clinicians to assess the technology’s risk to patients.

Bias: It should be ensured that the software was developed with data-driven AI methods that don’t perpetuate existing clinical biases. Researchers also suggested assessing the technology’s scalability and ability to protect patient privacy.

Patient-collected data is becoming much more prevalent in recent years, and as a result it has begun to play a substantial role in many recent organizational innovations and informatics projects. When patients bring this data to preventive and follow-up visits, they expect it to help care providers to inform their decision-making and improve their care. However, physicians and care providers often struggle to find value in and utilize this data due to gaps in training, confidence in security and privacy, as well as general lack of capabilities to use this data. As such, many organizations are calling for increased data literacy training so as to strategically drive the message of the overall capabilities of data.

So, how, where and what should we teach medical professionals to be data literate?

William Terry

Stickies

Lovies

Share this article

Arlen Meyers, MD, MBA

Healthcare Guru

Arlen Meyers, MD, MBA is a professor emeritus of otolaryngology, dentistry, and engineering at the University of Colorado School of Medicine and the Colorado School of Public Health and President and CEO of the Society of Physician Entrepreneurs at www.sopenet.org. He has created several medical device and digital health companies. His primary research centers around biomedical and health innovation and entrepreneurship and life science technology commercialization. He consults for and speaks to companies, governments, colleges and universities around the world who need his expertise and contacts in the areas of bio entrepreneurship, bioscience, healthcare, healthcare IT, medical tourism -- nationally and internationally, new product development, product design, and financing new ventures. He is a former Harvard-Macy fellow and In 2010, he completed a Fulbright at Kings Business, the commercialization office of technology transfer at Kings College in London. He recently published "Building the Case for Biotechnology." "Optical Detection of Cancer", and " The Life Science Innovation Roadmap". He is also an associate editor of the Journal of Commercial Biotechnology and Technology Transfer and Entrepreneurship and Editor-in-Chief of Medscape. In addition, He is a faculty member at the University of Colorado Denver Graduate School where he teaches Biomedical Entrepreneurship and is an iCorps participant, trainer and industry mentor. He is the Chief Medical Officer at www.bridgehealth.com and www.cliexa.com and Chairman of the Board at GlobalMindED at www.globalminded.org, a non-profit at risk student success network. He is honored to be named by Modern Healthcare as one of the 50 Most Influential Physician Executives of 2011 and nominated in 2012 and Best Doctors 2013.

BBN Times connects decision makers to you. Experts in their fields, worth listening to, are the ones who write our articles. We believe these are the real commentators of the future. We quickly and accurately deliver serious information around the world. BBN Times provides its readers human expertise to find trusted answers by providing a platform and a voice to anyone willing to know more about the latest trends. Stay tuned, the revolution has begun.